Why Cost May Limit Alzheimer’s Testing and Treatment

Alzheimer's diagnostic tests and newer treatments cost far more than most Americans can afford without insurance coverage, leaving millions unable to access early detection and care.

Alzheimer's diagnostic tests and newer treatments cost far more than most Americans can afford without insurance coverage, leaving millions unable to access early detection and care.

New blood tests and AI imaging tools are beginning to identify dementia earlier than ever, but access depends on insurance, geography, and race.

Newer dementia drugs work only for specific cognitive stages and require tests many patients can't access.

Aducanumab, an anti-amyloid monoclonal antibody developed by Biogen, prompted the first widespread awareness of this risk in 2020 when approximately 21%...

While clinical trials remain the gold standard for proving safety and efficacy, they enroll carefully selected participants who often don't represent the...

Families observe treatment changes doctors miss between appointments—tracking at home can guide medication decisions when documented systematically.

Drug companies measure Alzheimer's treatment success by tracking how slowly cognitive function declines, using tests, blood biomarkers, and brain imaging.

Families observe daily patterns that doctors can't—if they track changes systematically, those observations shape how Alzheimer's treatments are adjusted.

Drug companies measure Alzheimer's success through cognitive tests, brain imaging, and biomarkers, but these don't always predict what patients actually feel or how they function at home.

Sleep, diet, weight, and heart health form a tightly interconnected system where problems in one area cascade into the others.